Trelegy Ellipta 100 ug/1

Trelegy Ellipta 100 ug/1 is a combination inhaler containing fluticasone furoate, umeclidinium bromide, and vilanterol trifenatate. It is used for managing respiratory conditions like chronic obstructive pulmonary disease (COPD). This powder inhaler is designed for easy inhalation and is manufactured by GlaxoSmithKline LLC.

Trelegy Ellipta 100 ug/1 is primarily used for the maintenance treatment of chronic obstructive pulmonary disease (COPD). It combines three active ingredients to help improve lung function and reduce symptoms such as wheezing and shortness of breath. The inhaler is designed for long-term use and is not intended for immediate relief of acute symptoms. What is Trelegy Ellipta used for? It is used to manage COPD and may be prescribed by healthcare professionals for this purpose.

Common effects of Trelegy Ellipta 100 ug/1 may include throat irritation, headache, and a dry mouth. Some users might experience hoarseness or a cough after using the inhaler. These effects are generally mild and temporary. If any severe or persistent effects occur, it is advisable to consult a healthcare professional.

Trelegy Ellipta 100 ug/1 should be used as directed by a healthcare professional. It is important to follow the prescribed dosage and administration instructions. The inhaler should be stored in a clean, dry place and kept out of reach of children. Regular cleaning of the inhaler is recommended to maintain its effectiveness.

Trelegy Ellipta 100 ug/1 may interact with other medications, including beta-blockers, diuretics, and certain antibiotics. It is important to inform your healthcare professional about all medications you are taking to avoid potential interactions. Alcohol and other respiratory medications should be used with caution while using this inhaler.